Pfizer Says Pivotal Phase 3 BASIS Clinical Trial Of Marstaci

NEW YORK CITY (dpa-AFX) - Drug major Pfizer Inc. (PFE) announced Tuesday that the pivotal Phase 3 BASIS clinical trial (NCT03938792) evaluating marstacimab has met its primary endpoints, having

Related Keywords

, Pfizer Inc , Gefallene Big Techs , Pfizer , Ways , Pivotal , Hase , Basis , Linical , Trial , Marstacimab , Primary , Endpoints ,